Literature DB >> 25641203

The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features.

Mirhelen M Abreu1, Adriana Danowski2, Denis G Wahl3, Mary-Carmen Amigo4, Maria Tektonidou5, Marcelo S Pacheco2, Norma Fleming6, Vinicius Domingues7, Savino Sciascia8, Julia O Lyra9, Michelle Petri10, Munther Khamashta11, Roger A Levy12.   

Abstract

The purpose of this task force was to critically analyze nine non-criteria manifestations of APS to support their inclusion as APS classification criteria. The Task Force Members selected the non-criteria clinical manifestations according to their clinical relevance, that is, the patient-important outcome from clinician perspective. They included superficial vein thrombosis, thrombocytopenia, renal microangiopathy, heart valve disease, livedo reticularis, migraine, chorea, seizures and myelitis, which were reviewed by this International Task Force collaboration, in addition to the seronegative APS (SN-APS). GRADE system was used to evaluate the quality of evidence of medical literature of each selected item. This critical appraisal exercise aimed to support the debate regarding the clinical picture of APS. We found that the overall GRADE analysis was very low for migraine and seizures, low for superficial venous thrombosis, thrombocytopenia, chorea, longitudinal myelitis and the so-called seronegative APS and moderate for APS nephropathy, heart valve lesions and livedo reticularis. The next step can be a critical redefinition of an APS gold standard, for instance derived from the APS ACTION registry that will include not only current APS patients but also those with antiphospholipid antibodies not meeting current classification criteria.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Accuracy; Antiphospholipid Syndrome; Clinical features; GRADE system; Non-criteria manifestations

Mesh:

Substances:

Year:  2015        PMID: 25641203     DOI: 10.1016/j.autrev.2015.01.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  55 in total

1.  Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.

Authors:  Robert C Grenn; Srilakshmi Yalavarthi; Alex A Gandhi; Nayef M Kazzaz; Carlos Núñez-Álvarez; Diego Hernández-Ramírez; Antonio R Cabral; W Joseph McCune; Paula L Bockenstedt; Jason S Knight
Journal:  Ann Rheum Dis       Date:  2016-07-18       Impact factor: 19.103

2.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

3.  Chronic relapsing inflammatory optic neuropathy in a patient with triple antiphospholipid antibody positivity.

Authors:  Cristian Eduardo Navarro; Gabriel José Arango; María F Cubides
Journal:  Neurol Sci       Date:  2021-04-20       Impact factor: 3.307

4.  The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.

Authors:  Massimo Radin; Savino Sciascia; Doruk Erkan; Vittorio Pengo; Maria G Tektonidou; Amaia Ugarte; Pierluigi Meroni; Lanlan Ji; H Michael Belmont; Hannah Cohen; Guilherme Ramires de Jesús; D Ware Branch; Paul R Fortin; Laura Andreoli; Michelle Petri; Esther Rodriguez; Ignasi Rodriguez-Pinto; Jason S Knight; Tatsuya Atsumi; Rohan Willis; Emilio Gonzalez; Rosario Lopez-Pedrera; Ana Paula Rossi Gandara; Margarete Borges Gualhardo Vendramini; Alessandra Banzato; Ecem Sevim; Medha Barbhaiya; Maria Efthymiou; Ian Mackie; Maria Laura Bertolaccini; Danieli Andrade
Journal:  Semin Arthritis Rheum       Date:  2019-05-02       Impact factor: 5.532

Review 5.  Treatment of catastrophic antiphospholipid syndrome.

Authors:  Nayef M Kazzaz; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

Review 6.  Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.

Authors:  Cécile M Yelnik; Elizabeth Kozora; Simone Appenzeller
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

7.  Challenging cases in rheumatic pregnancies.

Authors:  Cuoghi Edens; Bruna Costa Rodrigues; Marcela Ignacchiti Lacerda; Flavia Cunha Dos Santos; Guilherme R De Jesús; Nilson Ramires De Jesús; Roger A Levy; Cianna Leatherwood; Jess Mandel; Bonnie Bermas
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

8.  Novel clinical and therapeutic aspects in autoimmunity.

Authors:  Howard Amital; Abdulla Watad; Zoltán Szekanecz
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

9.  In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis.

Authors:  He Meng; Srilakshmi Yalavarthi; Yogendra Kanthi; Levi F Mazza; Megan A Elfline; Catherine E Luke; David J Pinsky; Peter K Henke; Jason S Knight
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

10.  Longitudinally extensive transverse myelitis with anti-NMDA receptor antibodies during a systemic lupus erythematosus flare-up.

Authors:  Kentarou Takei; Mineshige Sato; Masashi Nakamura; Hiroshi Shimizu
Journal:  BMJ Case Rep       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.